Showing 1 posts of 1 posts found.
China has used Crispr/Cas9 gene-editing technology to edit the DNA of a human subject, suffering from metastatic lung cancer. This …
NHS England approves delayed-release treatment for rare kidney disease
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
Functional lung imaging offers new possibilities for respiratory care
Five Facts about cardiovascular disease
Data integrity: the keystone for AI adoption, patient safety and organisational reputation